PL362324A1 - Sztuczne białko o obniżonej immunogeniczności - Google Patents

Sztuczne białko o obniżonej immunogeniczności

Info

Publication number
PL362324A1
PL362324A1 PL36232402A PL36232402A PL362324A1 PL 362324 A1 PL362324 A1 PL 362324A1 PL 36232402 A PL36232402 A PL 36232402A PL 36232402 A PL36232402 A PL 36232402A PL 362324 A1 PL362324 A1 PL 362324A1
Authority
PL
Poland
Prior art keywords
fusion proteins
reduced immunogenicity
artificial fusion
artificial
immunogenicity
Prior art date
Application number
PL36232402A
Other languages
English (en)
Inventor
Stephen Gillies
Francis J. Carr
Tim Jones
Graham Carter
Anita Hamilton
Stephen Williams
Marian Hanlon
John Watkins
Matthew Baker
Jeffrey C. Way
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL362324A1 publication Critical patent/PL362324A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL36232402A 2001-02-19 2002-02-18 Sztuczne białko o obniżonej immunogeniczności PL362324A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01103955 2001-02-19
EP01108291 2001-04-05
PCT/EP2002/001690 WO2002066514A2 (en) 2001-02-19 2002-02-18 Artificial fusion proteins with reduced immunogenicity

Publications (1)

Publication Number Publication Date
PL362324A1 true PL362324A1 (pl) 2004-10-18

Family

ID=26076484

Family Applications (1)

Application Number Title Priority Date Filing Date
PL36232402A PL362324A1 (pl) 2001-02-19 2002-02-18 Sztuczne białko o obniżonej immunogeniczności

Country Status (13)

Country Link
US (2) US7189830B2 (pl)
EP (1) EP1361891A2 (pl)
JP (1) JP2004532620A (pl)
KR (1) KR20040074587A (pl)
CN (1) CN100522242C (pl)
AU (1) AU2002233340B2 (pl)
BR (1) BR0207267A (pl)
CA (1) CA2438628A1 (pl)
HU (1) HUP0303171A2 (pl)
MX (1) MXPA03007323A (pl)
PL (1) PL362324A1 (pl)
RU (1) RU2363707C2 (pl)
WO (1) WO2002066514A2 (pl)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693296C (en) * 1997-12-08 2013-09-10 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
BR9909583A (pt) * 1998-04-15 2002-01-15 Lexigen Pharm Corp Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese
AU775422B2 (en) * 1998-06-15 2004-07-29 Gtc Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (de) * 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
ATE336514T1 (de) * 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
EP1294401B1 (en) * 2000-06-29 2007-08-01 EMD Lexigen Research Center Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP4309662B2 (ja) * 2001-05-03 2009-08-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍特異的組換え抗体およびその使用
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP2354791A1 (en) * 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
ES2327409T3 (es) * 2003-03-26 2009-10-29 Apogenix Gmbh Proteinas de fusion fc mejoradas.
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
WO2005018572A2 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
KR101229731B1 (ko) * 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
EP1682584B1 (en) * 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
EP1699821B1 (en) * 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
JP4987484B2 (ja) 2004-01-22 2012-07-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 補体結合が低下した抗癌抗体
US7674464B2 (en) * 2004-03-04 2010-03-09 The University Of Tennessee Research Foundation Intracellular interleukin-1 receptor antagonists
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
WO2006012415A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
CN101072587B (zh) 2004-07-26 2012-12-26 比奥根艾迪克Ma公司 抗-cd154抗体
NZ552842A (en) * 2004-08-03 2010-05-28 Univ Columbia Rage fusion proteins and methods of use
AP2007003869A0 (en) * 2004-08-03 2007-02-28 Transtech Pharma Inc Rage fusion proteins and methods of use
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CN102746404B (zh) 2004-11-12 2016-01-20 赞科股份有限公司 对FcRn的结合被改变的Fc变体
CA2591297C (en) * 2004-12-09 2015-01-13 Stephen D. Gillies Il-7 variants with reduced immunogenicity
AU2006204791A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc Antibodies and Fc fusion proteins with altered immunogenicity
US20090202472A1 (en) * 2005-02-15 2009-08-13 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US20070134234A1 (en) * 2005-09-29 2007-06-14 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
CN101360759A (zh) * 2005-11-07 2009-02-04 哥本哈根大学 神经营养因子衍生的肽序列
CA2633766C (en) 2005-12-21 2016-06-28 Micromet Ag Pharmaceutical compositions comprising a bispecific single chain antibody with specificity for human cd3 and human cea and having resistance to soluble cea
RU2431804C2 (ru) * 2005-12-23 2011-10-20 ДжиКоудер Системз АБ Шаблон позиционирования
DK1966245T3 (da) 2005-12-30 2011-07-18 Merck Patent Gmbh Anti-CD19-Antistoffer med reduceret immunogenicitet
CN101351475B (zh) * 2005-12-30 2013-05-15 默克专利有限公司 具有提高的稳定性的白细胞介素12p40变体
NZ569545A (en) * 2006-02-09 2011-11-25 Transtech Pharma Inc Rage fusion proteins and methods of use for treating inflammation
ATE485517T1 (de) 2006-03-22 2010-11-15 Viral Logic Systems Technology Verfahren zur identifizierung von polypeptid- targets
EP2007815A2 (en) * 2006-03-31 2008-12-31 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors
CN100402551C (zh) * 2006-04-14 2008-07-16 中国科学院长春应用化学研究所 β2-微球蛋白的抗原表位及应用
MX2008013863A (es) 2006-05-05 2008-11-14 Transtech Pharma Inc Proteinas de fusion de rage y sus metodos de uso.
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
JP2009537145A (ja) * 2006-05-15 2009-10-29 バイラル ロジック システムズ テクノロジー コーポレーション 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法
US20080287320A1 (en) * 2006-10-04 2008-11-20 Codon Devices Libraries and their design and assembly
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
BRPI0812398A2 (pt) * 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
US8252897B2 (en) * 2007-06-21 2012-08-28 Angelica Therapeutics, Inc. Modified toxins
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
PL2235059T3 (pl) 2007-12-26 2015-08-31 Xencor Inc Warianty FC o zmodyfikowanym wiązaniu do FCRN
EA021967B1 (ru) * 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8470314B2 (en) * 2008-02-29 2013-06-25 Angelica Therapeutics, Inc. Modified toxins
WO2009149218A2 (en) * 2008-06-03 2009-12-10 Codon Devices, Inc. Novel proteins and methods of designing and using same
EP2362783A2 (en) 2008-10-31 2011-09-07 Biogen Idec MA Inc. Light targeting molecules and uses thereof
CA2749339A1 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
RU2011138951A (ru) 2009-02-23 2013-03-27 Сайтомкс Терапьютикс, Инк. Пропротеины и способы их применения
CN101863982A (zh) * 2009-04-17 2010-10-20 哈药集团生物工程有限公司 一种用于升高血小板的融合蛋白及其制备方法
CN102803292A (zh) 2009-04-20 2012-11-28 辉瑞公司 蛋白质糖基化的控制及其相关组合物和方法
CN102405230A (zh) * 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白
US8980843B2 (en) 2009-07-01 2015-03-17 Temple University—Of the Commonwealth System of Higher Education Leptin agonist and methods of use
MY160472A (en) 2009-07-17 2017-03-15 Bioatla Llc Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
WO2011098095A1 (en) * 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
JP5840148B2 (ja) 2010-03-04 2016-01-06 フェニックス インク． 変性させることなく可溶性組換えインターフェロンタンパク質を産生する方法
CA2794740C (en) 2010-04-01 2019-12-31 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
AU2011248540B2 (en) * 2010-04-28 2014-11-20 Oncolmmune, Inc. Methods of use of soluble CD24 for therapy of rheumatoid arthritis
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
SG187033A1 (en) 2010-07-16 2013-02-28 Bioatla Llc Novel methods of protein evolution
ES2899186T3 (es) 2010-12-31 2022-03-10 Bioatla Inc Humanización rápida de anticuerpos
WO2012092376A2 (en) 2010-12-31 2012-07-05 Short Jay M Comprehensive monoclonal antibody generation
WO2012111438A1 (ja) * 2011-02-18 2012-08-23 国立大学法人京都大学 組織再生用材料、これを含むタンパク質水溶液及びこれをゲル化させる方法
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
CN104093414A (zh) 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
CN104583239B (zh) 2012-05-10 2018-09-18 生物蛋白有限公司 多特异单克隆抗体
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
EA030389B1 (ru) 2013-05-28 2018-07-31 Проклара Байосайенсиз, Инк. ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ ИЗМЕНЕННУЮ АМИНОКИСЛОТНУЮ ПОСЛЕДОВАТЕЛЬНОСТЬ g3p БАКТЕРИОФАГА С ПОНИЖЕННОЙ ИММУНОГЕННОСТЬЮ
MY175896A (en) 2013-07-09 2020-07-14 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
EP2840091A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
US11293929B2 (en) 2014-01-07 2022-04-05 Bioatla, Inc. Proteins targeting orthologs
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP2017514458A (ja) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
KR20170052526A (ko) * 2014-03-13 2017-05-12 프로테나 바이오사이언시즈 리미티드 다발성 경화증에 대한 병용 치료
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
BR112017009297B1 (pt) * 2014-11-05 2024-02-15 Annexon, Inc Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
EP3227313B1 (en) 2014-12-03 2022-02-09 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
JP6907199B2 (ja) * 2015-10-30 2021-07-21 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｄ−タンパク質リガンドの構造ベース設計
GB201520545D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3380518A4 (en) 2015-11-24 2019-07-31 Annexon, Inc. ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOF
GB201607521D0 (en) * 2016-04-29 2016-06-15 Oncolmmunity As Method
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
AU2017340028A1 (en) * 2016-10-04 2019-05-23 The Council Of The Queensland Institute Of Medical Research Peptide libraries and methods of use
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
ES2893249T3 (es) * 2016-11-09 2022-02-08 Philogen Spa Inmunoconjugados que comprenden IL-2, anticuerpo anti-fibronectina y TNF-alfa mutante
US11332727B2 (en) 2017-03-14 2022-05-17 The Regents Of The University Of California Method for reducing an immune response by administering an immune evading adeno-associated AAV8 or AAVDJ viral vector
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
US11541121B2 (en) 2017-07-13 2023-01-03 City Of Hope Phosphorothioate-conjugated peptides and methods of using the same
WO2019014650A1 (en) * 2017-07-13 2019-01-17 City Of Hope ANTICANCER CONJUGATES OF PEPTIDE COUPLED WITH PHOSPHOROTHIOATE AND METHODS OF USE THEREOF
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
EP4037700A2 (en) 2019-10-03 2022-08-10 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
CN112457399B (zh) * 2020-12-19 2023-09-01 上海佰君生物科技有限公司 一种人免疫球蛋白g的提纯方法
CN112466390B (zh) * 2020-12-19 2023-11-14 广东众源药业有限公司 可用于纯化人免疫球蛋白g的疏水性环状肽配基
CN115724988B (zh) * 2021-08-26 2023-11-17 瑅安生物医药（杭州）有限公司 一种接近天然分子的多肽融合分子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
DE69833755T2 (de) * 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
DE19822406A1 (de) 1998-05-19 1999-11-25 Alexander Cherkasky Therapeutisches Präparat: Monoklonale Immunogenische Protease (MIP)/Monoklonales Immunogenisches Chymotrypsin (MIC)
CN1202128C (zh) * 1998-12-08 2005-05-18 拜奥威神有限公司 修饰蛋白的免疫原性
BR0007414A (pt) * 1999-01-07 2001-10-16 Lexigen Pharm Corp Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
DE19925052B4 (de) 1999-06-01 2012-01-12 Alexander Cherkasky Proteinkomplexe für den zielgerichteten Transport von (Poly)Peptide und Nukleinsäuren und sequenzspezifische Integration von DNA-Vektoren
CA2438513C (en) * 2001-02-19 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified anti-egfr antibodies with reduced immunogenicity
DE10133071A1 (de) 2001-07-07 2003-03-06 Alexander Cherkasky Antigene, Rezeptoren, Liganden oder ihre Regionen kombiniert mit proteolytischer Aktivität

Also Published As

Publication number Publication date
WO2002066514A3 (en) 2003-02-13
CN100522242C (zh) 2009-08-05
MXPA03007323A (es) 2003-12-12
RU2363707C2 (ru) 2009-08-10
US7189830B2 (en) 2007-03-13
RU2003127387A (ru) 2005-03-27
CA2438628A1 (en) 2002-08-29
US7615217B2 (en) 2009-11-10
KR20040074587A (ko) 2004-08-25
HUP0303171A2 (hu) 2003-12-29
US20040082039A1 (en) 2004-04-29
CN1492768A (zh) 2004-04-28
EP1361891A2 (en) 2003-11-19
US20070269435A1 (en) 2007-11-22
AU2002233340B2 (en) 2008-05-22
WO2002066514A2 (en) 2002-08-29
JP2004532620A (ja) 2004-10-28
BR0207267A (pt) 2004-02-10

Similar Documents

Publication Publication Date Title
PL362324A1 (pl) Sztuczne białko o obniżonej immunogeniczności
AU2002364586A8 (en) Albumin fusion proteins
AU2002364587A8 (en) Albumin fusion proteins
IL166751A0 (en) Modified transferin-antibody fusion proteins
GB0209778D0 (en) Spine fusion implant
HUP1300326A2 (en) Glp-1 fusion proteins
EP1276849A4 (en) ALBUMIN FUSION PROTEINS
AU2003239365A8 (en) Recombinant glycosyltransferase fusion proteins
PT1361893E (pt) Anticorpos anti-rfce modificados com imunogenicidade reduzida
AU2003210806A8 (en) Heterologous g-csf fusion proteins
EP1594530A4 (en) HYBRID PROTEINS OF ALBUMIN
EP1611093A4 (en) FUSION PROTEINS WITH MODIFIED TRANSFERRIN
IL158751A0 (en) Recombinant fusion proteins and the trimers thereof
AU2001291049A1 (en) Defensin-antigen fusion proteins
AU2002332041A1 (en) Albumin fusion proteins
HUP0402496A3 (en) Growth hormone fusion protein
GB9913437D0 (en) Fusion proteins
IL148550A0 (en) Transgenically produced fusion proteins
GB0200689D0 (en) Fusion proteins
AU2002322416A1 (en) Gfp fusion proteins and their use
AU2003276846A8 (en) Thrombopoiesis-stimulating proteins having reduced immunogenicity
AU2002306943A1 (en) Reducing the immunogenicity of fusion proteins
SI1463751T1 (sl) Albumin-fuzijski proteini
AU2001231918A1 (en) Scscntfr/nnt-1 fusion protein
TW567836U (en) Artificial joint with four-axial link

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)